SCHEMBL21526036

SCHEMBL21526036

CC(C)NC(C)C.COc1nc(C(=O)O)nc(C)c1Cc1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ TP53 P04637 6/20 0.39
▸ MAPT P10636 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 3/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PDE3B Q13370 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ENPP1 P22413 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21525996 0.92 SMN1; SMN2 (0.48) SMN1; SMN2TP53MAPTGAALMNA
SCHEMBL21526102 0.91 SMN1; SMN2 (0.47) SMN1; SMN2TP53MAPTGAALMNA
Tert-Butylamine SCHEMBL21526135 0.87 SMN1; SMN2 (0.44) SMN1; SMN2TP53MAPTGAALMNA
SCHEMBL21526041 0.84 SMN1; SMN2 (0.45) SMN1; SMN2TP53MAPTGAALMNA
SCHEMBL20356564 0.83 CCR4 (0.40) SMN1; SMN2MAPTGAA
SCHEMBL20356574 0.82 SMN1; SMN2 (0.38) SMN1; SMN2TP53MAPTLMNARXFP1
SCHEMBL21526092 0.81 SMN1; SMN2 (0.56) SMN1; SMN2TP53MAPTGAALMNA
SCHEMBL21525997 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TP53MAPTGAALMNA
SCHEMBL21526095 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TP53MAPTGAALMNA
Zinc Ion SCHEMBL21526080 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TP53MAPTGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-11034659-B2 Pyrimidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-15 — — US disclosed
US-20200172494-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-06-04 — — US disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034659-B2 Pyrimidine derivative GPR39, CFTR, TMEM109 SMN1; SMN2 2983/4885TP53 2921/4885MAPT 4880/4885
US-20200172494-A1 PYRIMIDINE DERIVATIVE GPR39, CFTR, TMEM109 SMN1; SMN2 2983/4885TP53 2921/4885MAPT 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback